Enhertu Approved in China as First and Only Tumor Agnostic HER2 Directed Medicine and Antibody Drug Conjugate for Previously Treated Patients with HER2 Positive Metastatic[...]

Daiichi Sankyo Co. Ltd. published this content on October 22, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 22, 2026 at 08:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]